Using this approach, we showed significant inhibition of EGFR and ERK in the post-treatment samples, consistent with EGFR signalling playing an important role in the downstream activation of the ERK pathway in colorectal cancer, and the successful disruption of this pathway by erlotinib. This evidence concerns the gene EGFR and colorectal cancer.